{"id":"vonicog-alfa","rwe":[],"tags":[{"label":"Biologic","category":"modality"},{"label":"B02BD06","category":"atc"},{"label":"Active","category":"status"},{"label":"von Willebrand disorder","category":"indication"},{"label":"Baxalta US Inc.","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Headache","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Generalized pruritus","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Vertigo","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"0.8%","severity":"common","organSystem":""},{"effect":"Infusion site paresthesia","drugRate":"0.8%","severity":"common","organSystem":""},{"effect":"Hot flush","drugRate":"0.8%","severity":"common","organSystem":""},{"effect":"Dysgeusia","drugRate":"0.8%","severity":"common","organSystem":""},{"effect":"Tremor","drugRate":"0.8%","severity":"common","organSystem":""},{"effect":"Electrocardiogram T wave inversions","drugRate":"0.8%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Infusion-related reaction","drugRate":"0.8%","severity":"serious"},{"effect":"Deep vein thrombosis","drugRate":"0.8%","severity":"serious"},{"effect":"Hypersensitivity/Anaphylactic reaction","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Baxalta US Inc.","patents":[{"type":"Biologic Exclusivity","filed":"December 08, 2015","source":"FDA Purple Book","status":"Active","expires":"January 28, 2029","territory":"US","patentNumber":"BLA 125577"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=VONICOG ALFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:11:44.571559+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:11:44.571474+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Vonicog Alfa","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:11:51.999258+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:11:50.342209+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:11:44.638313+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VONICOG ALFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:11:50.803217+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: von Willebrand factor exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:11:51.999191+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107873/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:11:51.652429+00:00"}},"allNames":"vonvendi","offLabel":[],"synonyms":["vonicog alfa","vonvendi","BAX 111","BAX111","von Willebrand factor","von Willebrand factor (recombinant)"],"timeline":[{"date":"2015-12-08","type":"positive","source":"DrugCentral","milestone":"FDA approval (Baxalta US Inc.)"},{"date":"2018-08-08","type":"positive","source":"DrugCentral","milestone":"EMA approval (Baxalta Innovations Gmbh)"},{"date":"2020-03-25","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Shire Japan K.K.)"}],"approvals":[{"date":"2015-12-08","orphan":false,"company":"Baxalta US Inc.","regulator":"FDA"},{"date":"2018-08-08","orphan":false,"company":"BAXALTA INNOVATIONS GMBH","regulator":"EMA"},{"date":"2020-03-25","orphan":true,"company":"Shire Japan K.K.","regulator":"PMDA"}],"brandName":"Vonvendi","ecosystem":[{"indication":"von Willebrand disorder","otherDrugs":[{"name":"desmopressin","slug":"desmopressin","company":"Ferring Pharms Inc"},{"name":"vasopressin","slug":"vasopressin","company":"Parke Davis"}],"globalPrevalence":null}],"mechanism":{"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Vonvendi is a recombinant von Willebrand factor replacement therapy that mimics the natural protein, providing hemostasis and preventing bleeding complications in patients with von Willebrand disorder."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Vonicog_alfa","title":"Vonicog alfa","extract":"Vonicog alfa, sold under the brand names Vonvendi and Veyvondi, is a medication used to control bleeding in adults with von Willebrand disease. It is a recombinant von Willebrand factor."},"commercial":{"launchDate":"2015","_launchSource":"DrugCentral (FDA 2015-12-08, Baxalta US Inc.)"},"purpleBook":{"bla":"125577","source":"FDA Purple Book","approvalDate":"December 08, 2015","licenseStatus":"Licensed","exclusivityExpiry":"January 28, 2029"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5173","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VONICOG%20ALFA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VONICOG ALFA","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Vonicog_alfa","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://purplebooksearch.fda.gov/","fields":["biologicExclusivity"],"source":"FDA Purple Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T16:09:41.685339","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:11:53.272128+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"vonicog alfa","indications":{"approved":[{"name":"von Willebrand disorder","source":"DrugCentral","snomedId":128105004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06433778","phase":"","title":"A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-12-16","conditions":["Von Willebrand Disease (VWD)"],"enrollment":34,"completionDate":"2023-10-30"},{"nctId":"NCT07404644","phase":"","title":"An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-02-19","conditions":["Von Willebrand Disease (vWD)"],"enrollment":13,"completionDate":"2031-05-30"},{"nctId":"NCT07129343","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-10-13","conditions":["Von Willebrand Disease (VWD)"],"enrollment":20,"completionDate":"2027-11-25"},{"nctId":"NCT05582993","phase":"PHASE3","title":"A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-06","conditions":["Von Willebrand Disease (VWD)"],"enrollment":24,"completionDate":"2030-04-11"},{"nctId":"NCT03879135","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2019-04-01","conditions":["Von Willebrand Disease (VWD)"],"enrollment":38,"completionDate":"2025-01-30"},{"nctId":"NCT06173024","phase":"","title":"Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)","status":"AVAILABLE","sponsor":"Takeda","startDate":"","conditions":["Von Willebrand Disease (VWD)"],"enrollment":0,"completionDate":""},{"nctId":"NCT02932618","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)","status":"RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2017-11-06","conditions":["Von Willebrand Disease"],"enrollment":31,"completionDate":"2026-03-31"},{"nctId":"NCT02606045","phase":"PHASE3","title":"Minimize Menorrhagia in Women With Von Willebrand Disease","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2019-02-07","conditions":["Von Willebrand Diseases"],"enrollment":39,"completionDate":"2022-08-30"},{"nctId":"NCT05265078","phase":"","title":"A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-06-08","conditions":["Von Willebrand Disease (VWD)"],"enrollment":102,"completionDate":"2023-04-06"},{"nctId":"NCT02973087","phase":"PHASE3","title":"rVWF IN PROPHYLAXIS","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-11-16","conditions":["Von Willebrand Disease"],"enrollment":29,"completionDate":"2020-07-06"}],"_emaApprovals":[{"date":"2018-08-08","status":"Authorised","company":"BAXALTA INNOVATIONS GMBH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"22168","NDDF":"007302","UNII":"5PKM8P0G5I","VANDF":"4025436","INN_ID":"9215","RXNORM":"11274","UMLSCUI":"C4291409","chemblId":"CHEMBL2107873","ChEMBL_ID":"CHEMBL2107873","KEGG_DRUG":"D08681","DRUGBANK_ID":"DB12872","SNOMEDCT_US":"121227005","IUPHAR_LIGAND_ID":"6755","MESH_DESCRIPTOR_UI":"D014841"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2015-","companyName":"Baxalta US Inc.","relationship":"Original Developer"},{"period":"2018","companyName":"Baxalta Innovations Gmbh","relationship":"EMA Licensee"},{"period":"2020","companyName":"Shire Japan K.K.","relationship":"PMDA Licensee"}],"publicationCount":17,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"B02BD06","allCodes":["B02BD06","B02BD10"]},"biosimilarFilings":[],"originalDeveloper":"Baxalta US Inc.","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Baxalta US Inc.","companyId":"baxalta-us-inc","modality":"Recombinant protein","firstApprovalDate":"2015","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-12-08T00:00:00.000Z","mah":"Baxalta US Inc.","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2015-12-08T00:00:00.000Z","mah":"Baxalta US Inc.","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2015-12-08T00:00:00.000Z","mah":"Baxalta US Inc.","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2015-12-08T00:00:00.000Z","mah":"Baxalta US Inc.","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2015-12-08T00:00:00.000Z","mah":"Baxalta US Inc.","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2015-12-08T00:00:00.000Z","mah":"Baxalta US Inc.","brand_name_local":null,"application_number":null},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2020-03-25T00:00:00.000Z","mah":"Shire Japan K.K.","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:11:53.272128+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}